A1M Pharma AB has changed its name to Guard Therapeutics International AB
A1M Pharma was founded in 2008 by researchers at the University of Lund, Sweden. The goal is to develop and commercialize the product candidate ROSgard, and thereby contribute to a better and less harmful treatment of acute kidney disease.
The drug candidate ROSgard's key characteristics prevent damage from oxidative stress by protecting, cleaning and repairing exposed tissue. The kidneys are organs that are especially sensitive to damage related to oxidative stress. A1M Pharma has chosen to focus its clinical development on acute kidney damage associated with heart surgery. This is considered to be a very attractive indication based on ROSgard's mode of action, available preclinical data and developmental advantages.
Treatment with ROSgard could save lives and prevent such chronic and grave consequences from reduced kidney function as life-supporting dialysis.
Our early clinical trials programme consists of two phase I studies on healthy subjects and one phase Ib study on patients undergoing open-heart surgery.Read more